CardioTech/Gish Introduces Downsized On-Pump Bypass System
This article was originally published in The Gray Sheet
CardioTech's Gish Biomedical subsidiary will launch its anticoagulant-coated, "on-pump" cardiac bypass system in July following 510(k) clearance of the system's six components, announced June 18
You may also be interested in...
Future trials comparing beating- and stopped-heart cardiopulmonary bypass surgery should address patient risk profiles, mortality and complications, a study published in the Jan. 30 New England Journal of Medicine states
CardioTech will use Gish clean room facilities to manufacture polyurethane coronary artery bypass grafts after acquiring the Rancho Santa Margarita, California heart surgery products company for about $7.3 mil. in stock on Oct. 30. The deal also will increase CardioTech revenues by over 500%. CardioTech reported revenue of $3.2 mil. for the year ended March 31, while Gish had sales of $16 mil. in 2001...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.